HK1078470A1 - Transdermal drug delivery matrix for coadministering estradiol and another steroid - Google Patents

Transdermal drug delivery matrix for coadministering estradiol and another steroid

Info

Publication number
HK1078470A1
HK1078470A1 HK05110412.4A HK05110412A HK1078470A1 HK 1078470 A1 HK1078470 A1 HK 1078470A1 HK 05110412 A HK05110412 A HK 05110412A HK 1078470 A1 HK1078470 A1 HK 1078470A1
Authority
HK
Hong Kong
Prior art keywords
estradiol
steroid
matrix
drug delivery
transdermal drug
Prior art date
Application number
HK05110412.4A
Other languages
English (en)
Inventor
Venkateshwaran Srinivasan
Charles D Ebert
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of HK1078470A1 publication Critical patent/HK1078470A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05110412.4A 1996-07-19 2005-11-18 Transdermal drug delivery matrix for coadministering estradiol and another steroid HK1078470A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/683,892 US5783208A (en) 1996-07-19 1996-07-19 Transdermal drug delivery matrix for coadministering estradiol and another steroid

Publications (1)

Publication Number Publication Date
HK1078470A1 true HK1078470A1 (en) 2006-03-17

Family

ID=24745888

Family Applications (2)

Application Number Title Priority Date Filing Date
HK00100001A HK1020864A1 (en) 1996-07-19 2000-01-03 Transdermal drug delivery matrix for coadministering estradiol and another steroid
HK05110412.4A HK1078470A1 (en) 1996-07-19 2005-11-18 Transdermal drug delivery matrix for coadministering estradiol and another steroid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK00100001A HK1020864A1 (en) 1996-07-19 2000-01-03 Transdermal drug delivery matrix for coadministering estradiol and another steroid

Country Status (21)

Country Link
US (1) US5783208A (xx)
EP (1) EP0921774B1 (xx)
JP (2) JP4212115B2 (xx)
KR (1) KR100628796B1 (xx)
CN (2) CN1204859C (xx)
AT (1) ATE339172T1 (xx)
AU (1) AU714590B2 (xx)
BR (1) BR9710738A (xx)
CA (1) CA2259532C (xx)
DE (1) DE69736671T2 (xx)
DK (1) DK0921774T3 (xx)
ES (1) ES2271970T3 (xx)
HK (2) HK1020864A1 (xx)
HU (1) HUP9904369A3 (xx)
IL (1) IL127708A (xx)
NO (1) NO325232B1 (xx)
NZ (1) NZ333558A (xx)
PL (1) PL188009B1 (xx)
PT (1) PT921774E (xx)
WO (1) WO1998003137A1 (xx)
ZA (1) ZA976035B (xx)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DK0836506T4 (da) * 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
DE19834007C1 (de) * 1998-07-29 2000-02-24 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung
BR9814415A (pt) * 1998-10-23 2000-10-10 Idea Innovat Dermale Appl Gmbh "método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis"
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
WO2000034461A2 (en) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions and methods of modulating cholesterol metabolism
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
DK1031346T3 (da) 1999-01-27 2002-08-12 Idea Ag Ikke-invasiv vaccination gennem huden
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6406745B1 (en) 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
CN101843601A (zh) * 2000-04-26 2010-09-29 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
KR20040029415A (ko) * 2001-08-10 2004-04-06 히사미쯔 제약 주식회사 경피 흡수형 제제
KR20030041596A (ko) * 2001-11-20 2003-05-27 삼일페인트공업 주식회사 의료용 팻치에 적용되는 아크릴 점착제의 제조방법
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
WO2006050926A2 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
CN101287470B (zh) 2005-10-12 2012-10-17 优尼麦德药物股份有限公司 改良的睾酮凝胶及使用方法
WO2007059979A2 (en) * 2005-11-23 2007-05-31 Universität Zürich Allergy treatment by epicutaneous allergen administration
CN101370453B (zh) * 2005-12-14 2013-12-18 努沃研究公司 用于皮肤输送药物的组合物和方法
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8084443B2 (en) 2007-10-01 2011-12-27 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
CA2667678A1 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
HUE030719T2 (en) 2007-04-09 2017-05-29 Univ Florida RAAV vector formulations and methods comprising tyrosine-modified capsid proteins for their use
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
CN105821079B (zh) 2010-04-23 2021-10-26 佛罗里达大学研究基金公司 用于治疗莱伯氏先天性黑蒙-1(lca1)的raav-鸟苷酸环化酶组合物及方法
CA3066596A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
WO2012145624A2 (en) 2011-04-21 2012-10-26 University Of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US10149834B2 (en) 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
WO2013081102A1 (ja) * 2011-12-01 2013-06-06 帝國製薬株式会社 ロピニロール含有貼付剤
WO2013112916A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
WO2015143078A1 (en) 2014-03-18 2015-09-24 University Of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
EP3134522B1 (en) 2014-04-25 2021-10-06 University of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
EP3200830B1 (en) 2014-10-03 2020-09-09 University of Massachusetts High efficiency library-identified aav vectors
RU2738421C2 (ru) 2014-10-21 2020-12-14 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
EP3233131A1 (en) 2014-12-16 2017-10-25 Board of Regents of the University of Nebraska Gene therapy for juvenile batten disease
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
CA3007301A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
SG11201806663TA (en) 2016-03-03 2018-09-27 Univ Massachusetts Closed-ended linear duplex dna for non-viral gene transfer
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
KR20190075964A (ko) 2016-10-13 2019-07-01 유니버시티 오브 매사추세츠 Aav 캡시드 설계
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
AU2019237514A1 (en) 2018-03-23 2020-10-08 University Of Massachusetts Gene therapeutics for treating bone disorders
CA3098448A1 (en) 2018-04-27 2019-10-31 University Of Massachusetts Aav capsids identified by in vivo library selection
US20220033824A1 (en) 2018-11-29 2022-02-03 University Of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors
EP3927380A1 (en) 2019-02-22 2021-12-29 University of Massachusetts Oxr1 gene therapy
CN114555814A (zh) 2019-09-13 2022-05-27 罗特格斯新泽西州立大学 Aav相容的层粘连蛋白-连接子聚合蛋白
WO2021168362A1 (en) 2020-02-21 2021-08-26 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
CA3177182A1 (en) 2020-03-31 2021-10-07 University Of Massachusetts Aav capsids variants and uses thereof
US20230212256A1 (en) 2020-05-21 2023-07-06 Board Of Regents, The University Of Texas System T cell receptors with vgll1 specificity and uses thereof
BR112023003023A2 (pt) 2020-08-17 2023-04-11 Massachusetts Inst Technology Abordagens de terapia com gene shank3
EP4255457A1 (en) 2020-12-03 2023-10-11 University of Massachusetts Development of novel gene therapeutics for fibrodysplasia ossificans progressiva
AU2022272489A1 (en) 2021-05-10 2023-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pharmaceutical compositions for treating neurological conditions
IL311572A (en) 2021-09-30 2024-05-01 Akouos Inc Compositions and methods for treating KCNQ4-related hearing loss
WO2023164545A1 (en) 2022-02-23 2023-08-31 Massachusetts Institute Of Technology Methods for upregulating shank3 expression

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
IL61721A (en) * 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
JPS60123417A (ja) * 1983-12-07 1985-07-02 Nitto Electric Ind Co Ltd 薬物投与部材
JPS6160620A (ja) * 1984-09-03 1986-03-28 Teijin Ltd ピログルタミン酸エステル類を含有する医薬品組成物
US5296230A (en) * 1985-02-25 1994-03-22 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4762851A (en) * 1985-11-29 1988-08-09 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
GB8811408D0 (en) * 1988-05-13 1988-06-15 Unilever Plc Cosmetic composition
DE68920109T2 (de) * 1988-10-11 1995-05-11 Shire Holdings Ltd Arzneimittelpräparat für perkutane Absorption.
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
JPH04342532A (ja) * 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収貼付剤
JP3086288B2 (ja) * 1991-07-23 2000-09-11 扶桑薬品工業株式会社 経皮吸収製剤
JP2948423B2 (ja) * 1992-08-19 1999-09-13 富士写真フイルム株式会社 カリウムイオン分析用イオン選択電極
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
BR9408457A (pt) * 1993-12-27 1997-08-05 Akzo Nobel Nv Preparação farmacêutica percutânia
FR2717688B1 (fr) * 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
JPH0827003A (ja) * 1994-07-22 1996-01-30 Sekisui Chem Co Ltd 経皮吸収製剤
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme

Also Published As

Publication number Publication date
HUP9904369A2 (hu) 2000-04-28
NO325232B1 (no) 2008-03-03
KR100628796B1 (ko) 2006-09-27
CA2259532C (en) 2008-10-07
JP4212115B2 (ja) 2009-01-21
AU714590B2 (en) 2000-01-06
CA2259532A1 (en) 1998-01-29
ATE339172T1 (de) 2006-10-15
HK1020864A1 (en) 2000-05-26
HUP9904369A3 (en) 2000-11-28
DE69736671T2 (de) 2007-09-13
EP0921774A4 (en) 1999-08-25
WO1998003137A1 (en) 1998-01-29
KR20000067934A (ko) 2000-11-25
IL127708A0 (en) 1999-10-28
CN100536835C (zh) 2009-09-09
NO990179L (no) 1999-01-15
JP2000514695A (ja) 2000-11-07
NZ333558A (en) 2000-05-26
CN1225568A (zh) 1999-08-11
ZA976035B (en) 1998-06-24
CN1636555A (zh) 2005-07-13
DK0921774T3 (da) 2007-01-29
CN1204859C (zh) 2005-06-08
IL127708A (en) 2004-02-19
EP0921774A1 (en) 1999-06-16
BR9710738A (pt) 1999-08-17
DE69736671D1 (de) 2006-10-26
PL331239A1 (en) 1999-07-05
AU3650397A (en) 1998-02-10
PL188009B1 (pl) 2004-11-30
JP2006342186A (ja) 2006-12-21
NO990179D0 (no) 1999-01-15
EP0921774B1 (en) 2006-09-13
US5783208A (en) 1998-07-21
PT921774E (pt) 2006-12-29
ES2271970T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
HK1078470A1 (en) Transdermal drug delivery matrix for coadministering estradiol and another steroid
NZ316026A (en) A transdermal therapeutic system (a hormone patch) in which drugs are contained which are released into the skin comprising a backing film and a pressure sensitive adhesive
GR3036144T3 (en) Transdermal delivery device
GR3033859T3 (en) Matrix for transdermal drug delivery
ZA977832B (en) Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents.
AU676826B2 (en) Transdermal therapeutic systems
EP0279977A3 (en) Transdermal administration of progesterone, estradiol esters and mixtures thereof
PT739199E (pt) Adesivo de estradiol com agente reforcador da penetracao
MX9602656A (es) Dispositivo transdermico que contiene pirrolidona polivinilica como mejorador de solubilidad.
RU98100451A (ru) Трансдермальный пластырь и способ введения 17-деацетилноргестимата отдельно или в сочетании с эстрогеном
AU3779399A (en) Drug-containing transdermal patches, plastisols and adhesives
CA2172265A1 (en) Transdermal delivery device containing an estrogen
IL128768A0 (en) Transdermal therapeutic system containing oestriol

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130702